109132 ⎘
Structure or type of the nucleic acid; Type of nucleic acid Antisense
COMPOSITIONS AND METHODS FOR INCREASING OR ENHANCING TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVING OR REDUCING IMMUNOGLOBULINS
#1202COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
#1203METHOD FOR TREATING CARDIOVASCULAR DISEASE
#1204COMPOSITIONS AND METHODS FOR TREATING CHRONIC MYELOMONOCYTIC LEUKEMIA
#1205DECOY TRANSCRIPTS FOR TREATMENT OF ssRNA VIRAL INFECTION
#1206ANTISENSE NUCLEIC ACID INDUCING SKIPPING OF EXON 51
#1207ANTISENSE SEQUENCES FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS
#1208COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
#1209GENE THERAPY FOR NEURODEGENERATIVE DISORDERS USING POLYNUCLEOTIDE SILENCING AND REPLACEMENT
#1210ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF USHER SYNDROME
#1211VIRAL VECTORS FOR TREATING NEUROGENIC DETRUSOR OVERACTIVITY
#1212METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS
#1213ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1214OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES
#1215USE OF CDON INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION
#1216EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST
#1217ANTISENSE OLIGONUCLEOTIDE OF ATN1
#1218UNC13A antisense oligonucleotides
#1219COMPOUNDS AND METHODS FOR MODULATING KCNQ2
#1220OLIGONUCLEOTIDES FOR MODULATING CD73 EXON 7 SPLICING
#1221USE OF COPS3 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#1222Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#1223USE OF SARAF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#1224METHODS FOR USING TRANSCRIPTION-DEPENDENT DIRECTED EVOLUTION OF AAV CAPSIDS
#1225Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
#1226COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION
#1227COMPOUNDS AND METHODS FOR MODULATING SPLICING OF PRE-MRNA
#1228ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES
#1229METHODS OF PREPARING OLIGONUCLEOTIDE COMPOSITIONS USING ULTRAFILTRATION/DIAFILTRATION
#1230Compounds and methods for reducing LRRK2 expression
#1231Selective Antisense Compounds and Uses Thereof
#1232Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
#1233Compositions for Modulating C9ORF72 Expression
#1234EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
#1235Compound and application thereof
#1236Polymerizable compound, compound, and method for producing boranophosphate oligomer
#1237METHODS OF TREATING SPINAL MUSCULAR ATROPHY
#1238MESENCHYMAL STROMAL CELLS AND EXTRACELLULAR VESICLES FOR TREATING VIRAL INFECTIONS, INFLAMMATION, AND TISSUE FIBROSIS
#1239EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#1240Compositions comprising reversibly modified oligonucleotides and uses thereof
#1241Treatment Of Glaucoma With Rho Guanine Nucleotide Exchange Factor 12 (ARHGEF12) Inhibitors
#1242COMPOSITIONS AND METHODS TO TREAT NEUROLOGICAL DISEASES
#1243Antisense nucleic acid inducing skipping of exon 51
#1244OLIGOMERIC COMPOUNDS COMPRISING BACKBONE CONSTRAINED MACROCYCLES
#1245ANTI-ADAM33 OLIGONUCLEOTIDES AND RELATED METHODS
#1246Compositions and methods for delivery of nucleic acids to cells
#1247Methods of treating cancers having a BRCA1 and/or BRCA2 mutation(s)
#1248ANTISENSE OLIGONUCLEOTIDE TARGETING LINC00518 FOR TREATING MELANOMA
#1249PRODUCTS AND COMPOSITIONS
#1250RAAV-MEDIATED IN VIVO DELIVERY OF SUPPRESSOR TRNAS
#1251Compositions and methods for delivery of nucleic acids to cells
#1252DRUG FOR CURATIVE THERAPY OF INTRACTABLE HEREDITARY RENAL ALPORT SYNDROME
#1253NON-HUMAN ANIMALS COMPRISING A HUMANIZED KLKB1 LOCUS AND METHODS OF USE
#1254ANTISENSE OLIGOMERS AND METHODS FOR TREATING PARKIN-RELATED PATHOLOGIES
#1255METHODS AND MATERIALS FOR TREATING CANCER
#1256Methods and compositions for reducing pathogenic isoforms
#1257Optimized anti-FLT1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
#1258COMPOSITIONS AND METHODS FOR TREATING OR AMELIORATING A MYCOBACTERIUM TUBERCULOSIS INFECTION
#1259TREATMENT OF THYMIC STROMAL LYMPHOPOIETIN (TSLP) RELATED DISEASES BY INHIBITION OF LONG-FORM TSLP TRANSCRIPTS
#1260Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same
#1261METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA
#1262Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
#1263Inhibitor of metadherin expression
#1264ANTAGONISM AS A THERAPY FOR TDP-43 PROTEINOPATHIES
#1265METHODS AND USES FOR PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) INHIBITORS
#1266TARGETED AND LOCALIZED IN VIVO DELIVERY OF OLIGONUCLEOTIDES
#1267ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES
#1268STABLE TARGET-EDITING GUIDE RNA HAVING CHEMICALLY MODIFIED NUCLEIC ACID INTRODUCED THEREINTO
#1269NEW METHOD FOR TARGETED EDITING OF RNA
#1270Methods of Treatment of Neurofibromatosis Type 1 (NF1) and NF-1 Mediated Conditions and Compositions for Use in Such Methods
#1271Modulation Of Endoplasmic Reticulum Aminopeptidase 2 (ERAP2)-Mediated Immune Response
#1272ANTISENSE GUIDE RNA WITH ADDED FUNCTIONAL REGION FOR EDITING TARGET RNA
#1273DOUBLE-STRANDED NUCLEIC ACID MOLECULES AND METHOD FOR REMOVING GLASS ADAPTOR IN DNA LIBRARY BY MEANS OF SAME
#1274Compositions and methods for modulating complement factor B expression
#1275RAB13 AND NET1 ANTISENSE OLIGONUCLEOTIDES TO TREAT METASTATIC CANCER
#1276Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors
#1277COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION
#1278INHIBITION OF DENND5B EXPRESSION FOR TREATING HEPATIC STEATOSIS
#1279Antisense Oligonucleotides Targeting ATXN3
#1280Polynucleotide compositions and methods for gene expression regulations
#1281siRNA based on RNA sequence of SARS-CoV-2 and use thereof
#1282Modulators of diacyglycerol acyltransferase 2 (DGAT2)
#1283Phosphorodiamidate morpholino oligomers
#1284TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
#1285ANTISENSE NUCLEIC ACID ENABLING EXON SKIPPING
#1286Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
#1287COMPOUNDS AND METHODS FOR MODULATING SCN1A EXPRESSION
#1288METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS
#1289METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXAPNSION DISORDERS ASSOCIATED WITH OGG1 ACTIVITY
#1290ANTI-SLC6A1 OLIGONUCLEOTIDES AND RELATED METHODS
#1291COMPOSITIONS AND METHODS FOR MODULATING ATAXIN 3 EXPRESSION
#1292ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF CANCER STEM CELLS
#1293VACCINIA VIRAL POLYMERASE-MEDIATED VIRAL REPLICATION
#1294Antisense oligonucleotides for nucleotide deamination in the treatment of Stargardt disease
#1295INHIBITORS OF KDM5A FOR USE IN TREATMENT OF IDIOPATHIC INFLAMMATORY MYOPATHIES
#1296Treatment Of Psoriasis With Interferon Induced Helicase C Domain 1 (IFIH1) Inhibitors
#1297ENGINEERING CIRCULAR GUIDE RNAS
#1298Targeting cell tropism receptors to inhibit cytomegalovirus infection
#1299SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#1300Compositions and methods for delivery of nucleic acids to cells
#1301Tunable Reversir™ compounds
#1302Implantable Medical Device for the Delivery of a Nucleic Acid
#1303Compositions and methods for organ specific delivery of nucleic acids
#1304Recombinant Adeno-Associated Virus Delivery of Exon 2-Targeted U7SNRNA Polynucleotide Constructs
#1305TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION
#1306Modulation of huntingtin expression
#1307IDENTIFYING NON-PRODUCTIVE SPLICE SITES
#1308COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS
#1309EXTRACELLULAR VESICLES WITH ANTISENSE OLIGONUCLEOTIDES TARGETING KRAS
#1310AN UBIQUITIN LIGASE INHIBITOR FOR USE FOR PREVENTING AND/OR TREATING A DISEASE LINKED WITH CEREBRAL HYPOPERFUSION
#1311ANTISENSE OLIGONUCLEOTIDES AND THIER USE FOR THE TREATMENT OF CANCER
#1312Modulators and modulation of the receptor for advanced glycation end-products RNA
#1313EXOSOMES-BASED THERAPY FOR LIVER FIBROSIS AND OTHER DISEASES WITH FIBROSIS
#1314METHODS AND COMPOSTIONS FOR INHIBITING P97
#1315METHOD OF TREATING CANCER AND METHOD OF SENSITIZING CANCER CELLS TO THE ACTION OF CHEMOTHERAPEUTIC AGENTS VIA GROWTH HORMONE RECEPTOR ANTAGONISTS OR KNOCK DOWN
#1316METHODS AND COMPOSTIONS FOR INHIBITING CORONAVIRAL REPLICATION
#1317IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME
#1318EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA
#1319Selective antisense compounds and uses thereof
#1320Muscle targeting complexes and uses thereof for treating dystrophinopathies
#1321Treatment Of Obesity With G-Protein Coupled Receptor 75 (GPR75) Inhibitors
#1322PIKFYVE antisense oligonucleotides
#1323ANTISENSE OLIGONUCLEOTIDE SEQUENCES FOR SILENCING THE HUMAN L1-MET TRANSCRIPT IN TUMORS
#1324Twist signaling inhibitor compositions and methods of using the same
#1325COMPOSITIONS AND METHODS FOR DECREASING TAU EXPRESSION
#1326Modulation of Angiopoietin-Like 3 Expression
#1327Selective reduction of allelic variants
#1328MODIFIED iRNA AGENTS
#1329Targeting Synaptogyrin-3 in Tauopathy Treatment
#1330COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF
#1331Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
#1332RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products, Compositions Thereof, and Methods of Use
#1333TREATMENT OF COVID-19 LUNG INJURY USING UMBILICAL CORD PLASMA BASED COMPOSITIONS
#1334Allele-specific silencing therapy for DFNA9 using antisense oligonucleotides
#1335RNA MODULATING OLIGONUCLEOTIDES WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
#1336EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
#1337ADOPTIVE CELL THERAPY USING SPHERICAL NUCLEIC ACIDS (SNAS)
#1338Compositions and methods for organ specific delivery of nucleic acids
#1339EXON SKIPPING OF FC-EPSILON-RI-BETA AND MS4A6A IN COMBINATION FOR THE TREATMENT OF ALLERGIC DISEASES
#1340TARGETING NONSENSE-MEDIATED DECAY TO ACTIVATE P53 PATHWAY FOR THE TREATMENT OF CANCER
#1341COMPOUNDS FOR MODULATING FC-EPSILON-RI-BETA EXPRESSION AND USES THEREOF
#1342PPM1A INHIBITORS AND METHODS OF USING SAME
#1343Modified antisense oligonucleotide for inhibition of FoxP3 expression
#1344COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
#1345Dynamic pharmacokinetic-modifying anchors
#1346Inhibitors Of RNA Editing And Uses Thereof
#1347ANTISENSE COMPOUNDS AND USES THEREOF
#1348FN3 domain-siRNA conjugates and uses thereof
#1349Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors
#1350EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#1351Promotion of Cardiomyocyte Proliferation and Regenerative Treatment of the Heart by Inhibition of microRNA-128
#1352PRODUCTS AND COMPOSITIONS
#1353ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 pre-mRNA
#1354Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
#1355EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
#1356MELANOPHILIN ANTISENSE OLIGONUCLEOTIDES
#1357METHODS AND COMPOSITIONS FOR TYPE 2 DIABETES THERAPY
#1358CORRECTION OF EXON SKIPPING IN MONOCYTE-DERIVED CELLS FOR IMPROVED IMMUNE RESPONSE
#1359NOVEL TUMOR-SPECIFIC ANTIGENS FOR OVARIAN CANCER AND USES THEREOF
#1360ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
#1361PHARMACEUTICAL COMPOSITION CONTAINING HERES EXPRESSION INHIBITOR FOR PREVENTING OR TREATING SQUAMOUS CELL CARCINOMA
#1362LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY
#1363OLIGONUCLEOTIDES FOR SYNGR-3 MODULATION
#1364LIPOSOMAL SPHERICAL NUCLEIC ACID (SNA) CONSTRUCTS FOR SPLICE MODULATION
#1365COMPOSITION FOR DIAGNOSIS OR TREATMENT OF A CONDITION ASSOCIATED WITH INCREASED ACTIVITY OF EIF4E COMPRISING AN EIF4E INHIBITOR
#1366GNAQ targeted dsRNA compositions and methods for inhibiting expression
#1367Compositions and methods for inhibiting nuclear receptor subfamily 1 group H member 3 (NR1H3) expression
#1368RNAI CONSTRUCTS FOR INHIBITING SLC30A8 EXPRESSION AND METHODS OF USE THEREOF
#1369METHODS FOR DEPLETION OF DELETERIOUS MITOCHONDRIAL GENOMES
#1370METHODS FOR THE TREATMENT OF RETINAL DYSTROPHIES BY EXON-SKIPPING STRATEGY
#1371CHEMICALLY MODIFIED OLIGONUCLEOTIDES FOR RNA EDITING
#1372INHIBITOR AGAINST EXPRESSION OF IMMUNE CHECKPOINT MOLECULE
#1373TREATMENT OF HR DEFICIENT CANCER
#1374METHODS OF TREATING OR SELECTING A TREATMENT FOR A SUBJECT RESISTANT TO TNF INHIBITOR USING A NLRP3 ANTAGONIST
#1375SYSTEMS AND METHODS FOR DETERMINING EFFECTS OF THERAPIES AND GENETIC VARIATION ON POLYADENYLATION SITE SELECTION
#1376Methods for creating bilayers for use with nanopore sensors
#1377MODULATORY POLYNUCLEOTIDES
#1378Antisense nucleic acid that induces skipping of exon 50
#1379NUCLEIC ACID THAT INHIBITS EXPRESSION OF MEX3B GENE, MEX3B GENE EXPRESSION INHIBITING AGENT, METHOD FOR INHIBITING MEX3B GENE EXPRESSION, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR DISEASE CAUSED BY MEX3B GENE EXPRESSION
#1380OLIGONUCLEOTIDES AND METHODS OF USE FOR TREATING NEUROLOGICAL DISEASES
#1381TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES
#1382INHIBITION OF MTHFD1L FOR USE IN HYPERTROPHIC HEART DISEASE AND HEART FAILURE
#1383CD71 binding fibronectin type III domains
#1384METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS
#1385OLIGONUCLEOTIDE, AND TARGET RNA SITE-SPECIFIC EDITING METHOD
#1386ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATING PENDRED SYNDROME
#1387COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION
#1388Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Protein Cleavage-Activating Protein (SCAP) Inhibitors
#1389SYNTHETIC LIPID-LIKE MATERIALS FOR BRAIN DELIVERY
#1390TREATMENT FOR SOD1 ASSOCIATED DISEASE
#1391Extended dicer substrate agents and methods for the specific inhibition of gene expression
#1392LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY
#1393COMPOUNDS AND METHODS FOR REDUCING SNCA EXPRESSION
#1394IMPROVED ANTIBODY-OLIGONUCLEOTIDE CONJUGATE
#1395Nucleic acid-polypeptide compositions and methods of inducing exon skipping
#1396COMPOSITION FOR PREVENTING OR TREATING CANCER
#1397INHIBITING APE2 EXPRESSION IN A SUBJECT TREATED WITH A DRUG AGENT THAT CAUSES INCREASED APE2 EXPRESSION
#1398RNA-Editing Enzyme-Recruiting Oligonucleotides and Uses Thereof
#1399ANTISENSE RNA EDITING OLIGONUCLEOTIDES COMPRISING CYTIDINE ANALOGS
#1400A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER
#1401DOUBLE-STRANDED NUCLEIC ACID COMPLEX AND USE THEREOF
#1402METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES
#1403OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
#1404PROCESS FOR FORMULATING AN ANIONIC AGENT
#1405Novel Retinitis Pigmentosa Treatment
#1406COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSION
#1407METHODS FOR TREATING MUSCULAR DYSTROPHY
#1408METHODS FOR TREATING MUSCULAR DYSTROPHY USING INHIBITORY OLIGONUCLEOTIDES TO CD49D
#1409Suppression of pathological angiogenesis by inhibition of NR2F6
#1410Antisense oligonucleotides rescue aberrant splicing of ABCA4
#1411USE OF MÜLLERIAN INHIBITING SUBSTANCE INHIBITORS FOR TREATING CANCER
#1412Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
#1413Compounds and methods for modulating ATXN1
#1414COMPOSITIONS AND METHODS FOR MODULATING SPLICING AND PROTEIN EXPRESSION
#1415ANTISENSE OLIGONUCLEOTIDE THERAPY FOR CANCER
#1416Muscle targeting complexes and uses thereof for treating dystrophinopathies
#1417GENERATION OF NEURONS BY REPROGRAMMING OF OLIGODENDROCYTES AND OLIGODENDROCYTE PRECURSOR CELLS
#1418METHOD OF MODULATING ADIPOSITY
#1419METHODS OF INDUCING INSULIN PRODUCTION
#1420COMPOUNDS AND METHODS USEFUL FOR MODULATING GENE SPLICING
#1421MOLECULAR TARGETED NUCLEIC ACID MEDICINE FOR GASTRIC CANCER
#1422EXON 44-TARGETED NUCLEIC ACIDS AND RECOMBINANT ADENO-ASSOCIATED VIRUS COMPRISING SAID NUCLEIC ACIDS FOR TREATMENT OF DYSTROPHIN-BASED MYOPATHIES
#1423OLIGONUCLEOTIDE THERAPY FOR STARGARDT DISEASE
#1424VH4 antibodies and compositions comprising the same
#1425METHODS OF TREATING P53 MUTANT CANCERS USING OGDH INHIBITORS
#1426Oligonucleotide interference treatments of prostate cancer
#1427CONJUGATE AND USES THEREOF
#1428ANTISENSE THERAPY FOR PTP1B RELATED CONDITIONS
#1429COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#1430GUIDE RNA FOR EDITING TARGET, WITH FUNCTIONAL NUCLEOTIDE SEQUENCE ADDED
#1431ß-AMYLOID CYCLIC RIBONUCLEIC ACID, POLYPEPTIDE, AND APPLICATION THEREOF
#1432SELECTIVE LOCAL INHIBITION OF TNFR1-MEDIATED FUNCTIONS AT THE SITE OF ANTIGEN/ALLERGEN PRESENTATION
#1433Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1434Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1435Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1436NUCLEIC ACID DRUG TARGETING MURF1
#1437METHODS FOR TREATING RAN PROTEIN-ASSOCIATED NEUROLOGICAL DISEASES
#1438Recombinant virus products and methods for inducing DUX4 exon skipping
#1439METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)
#1440COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEUKODYSTROPHY AND WHOLE ANIMAL AND CELLULAR MODELS FOR IDENTIFYING EFFICACIOUS AGENTS FOR TREATMENT OF THE SAME
#1441Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1442UBE3A ANTISENSE THERAPEUTICS
#1443COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION
#1444FUNCTIONAL NUCLEIC ACID MOLECULES UPREGULATING THE TRANSLATION OF A FRATAXIN MRNA
#1445VECTORS AND COMPOSITIONS FOR TREATING HEMOGLOBINOPATHIES
#1446EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#1447CANCER-TARGETED, VIRUS-ENCODED, REGULATABLE T (CATVERT) OR NK CELL (CATVERN) LINKERS
#1448METHODS FOR THE TREATMENT OF EPILEPSY
#1449ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES
#1450Compositions and methods for disrupting the molecular mechanisms associated with mitochondrial dysfunction and neurodegenerative disease
#1451METHOD FOR REDUCING TOXICITY OF ANTISENSE NUCLEIC ACIDS
#1452Enhanced oligonucleotides for inhibiting RTEL1 expression
#1453Methods and compositions for inhibiting PMP22 expression
#1454EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
#1455Treatment and detection of inherited neuropathies and associated disorders
#1456Compositions and Methods for Monitoring, Diagnosis, Detection and Treatment of Cancer
#1457ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF
#1458Modulators of Complement Factor B
#1459Modulators of MALAT1 expression
#1460COMPOUNDS AND METHODS FOR REDUCING FUS EXPRESSION
#1461COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION
#1462Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
#1463TARGETED RNA EDITING BY LEVERAGING ENDOGENOUS ADAR USING ENGINEERED RNAS
#1464Methods for treating VEGF-related conditions
#1465ANTICANCER COMBINATIONS
#1466Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
#1467METHODS FOR MODULATING IMMUNOGLOBULIN EXPRESSION
#1468Antisense oligonucleotides for the treatment of Leber congenital amaurosis
#1469NUCLEIC ACID COMPOSITIONS AND METHODS OF MULTI-EXON SKIPPING
#1470METHODS FOR CREATING INTEGRATION-FREE, VIRUS-FREE, EXOGENOUS ONCOGENE-FREE IPS CELLS AND COMPOSITIONS FOR USE IN SUCH METHODS
#1471NANOGOLD-DNA BIOCONJUGATES AND METHODS OF USE THEREOF
#1472USE OF CD9 AS A BIOMARKER AND AS A BIOTARGET IN GLOMERULONEPHRITIS OR GLOMERULOSCLEROSIS
#1473OLIGONUCLEOTIDE THERAPY FOR WOLMAN DISEASE AND CHOLESTERYL ESTER STORAGE DISEASE
#1474Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
#1475MICRO-RNA SITE BLOCKING OLIGONUCLEOTIDES FOR THE TREATMENT OF EPILEPTIC ENCEPHALOPATHY AND NEURODEVELOPMENTAL DISORDERS
#1476THERAPEUTIC TARGETS FOR FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#1477Compositions and Methods for Modulating MECP2 Expression
#1478Methods for production and quantification of unique molecular identifier-labeled beads
#1479SYNTHETIC PRODUCTION OF SINGLE-STRANDED ADENO ASSOCIATED VIRAL DNA VECTORS
#1480COMBINATION TREATMENTS FOR CYSTIC FIBROSIS CHARACTERIZED BY A 3849 + 10KB C-TO-T CFTR MUTATION
#1481PD-L1 antisense oligonucleotides for use in tumor treatment
#1482METHOD FOR INHIBITING INFECTION AND ACTIVATION OF VIRUS
#1483LIPID OLIGONUCLEOTIDE ANTISENSE AGAINST ANTIBIOTIC RESISTANCE
#1484MODULATORS OF TELOMERE DISEASE
#1485METHOD OF PRODUCING MICROBIAL OIL CONTAINING FATTY ACIDS OBTAINED FROM STRAMENOPILE
#1486Nucleic acids and methods for the treatment of Pompe disease
#1487ANGPTL2 ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
#1488RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATION
#1489ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF USHER SYNDROME
#1490Oral delivery of antisense conjugates targeting PCSK9
#1491MODULATION OF TRANSTHYRETIN EXPRESSION
#1492MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS
#1493METHODS AND COMPOSITIONS FOR BARCODING NUCLEIC ACID LIBRARIES AND CELL POPULATIONS
#1494Treatment of amyotrophic lateral sclerosis (ALS)
#1495Antisense oligonucleotide for targeting progranulin
#1496Antisense oligonucleotides for the treatment of Stargardt disease
#1497METHODS FOR TREATING CANCERS USING ANTISENSE
#1498TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#1499OLIGOMERS
#1500TAU-TARGETING OLIGONUCLEOTIDE GAPMERS